Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | ATOS |
---|---|---|
09:32 ET | 30483 | 1.86 |
09:34 ET | 5965 | 1.8561 |
09:36 ET | 18702 | 1.87 |
09:38 ET | 9700 | 1.865 |
09:39 ET | 4242 | 1.8695 |
09:41 ET | 12414 | 1.83 |
09:43 ET | 16056 | 1.8511 |
09:45 ET | 8610 | 1.8499 |
09:48 ET | 19849 | 1.8501 |
09:50 ET | 2355 | 1.87 |
09:52 ET | 1884 | 1.8786 |
09:54 ET | 69712 | 1.9 |
09:56 ET | 9180 | 1.9 |
09:57 ET | 14872 | 1.8801 |
09:59 ET | 3004 | 1.8899 |
10:01 ET | 300 | 1.89 |
10:03 ET | 100 | 1.88 |
10:06 ET | 200 | 1.8792 |
10:08 ET | 15000 | 1.88 |
10:10 ET | 7238 | 1.88 |
10:12 ET | 5115 | 1.9 |
10:14 ET | 14200 | 1.8993 |
10:15 ET | 22673 | 1.87 |
10:17 ET | 9890 | 1.88 |
10:19 ET | 2354 | 1.88 |
10:21 ET | 1493 | 1.89 |
10:24 ET | 7683 | 1.875 |
10:26 ET | 72299 | 1.89 |
10:28 ET | 11990 | 1.88 |
10:30 ET | 7958 | 1.9 |
10:32 ET | 20126 | 1.9 |
10:33 ET | 5308 | 1.89 |
10:35 ET | 2935 | 1.8983 |
10:37 ET | 900 | 1.9 |
10:39 ET | 5825 | 1.91 |
10:42 ET | 5121 | 1.9005 |
10:44 ET | 3681 | 1.91 |
10:46 ET | 6645 | 1.8901 |
10:48 ET | 10180 | 1.8901 |
10:50 ET | 11687 | 1.89 |
10:51 ET | 500 | 1.89 |
10:53 ET | 400 | 1.89 |
10:55 ET | 2199 | 1.9 |
10:57 ET | 2557 | 1.9 |
11:00 ET | 10665 | 1.9 |
11:02 ET | 6435 | 1.89 |
11:04 ET | 2198 | 1.885 |
11:06 ET | 15595 | 1.87 |
11:08 ET | 10845 | 1.8473 |
11:09 ET | 28976 | 1.85 |
11:11 ET | 1987 | 1.85 |
11:13 ET | 9249 | 1.86 |
11:15 ET | 39448 | 1.86 |
11:18 ET | 3200 | 1.86 |
11:20 ET | 6823 | 1.86 |
11:22 ET | 300 | 1.87 |
11:24 ET | 5800 | 1.87 |
11:26 ET | 3300 | 1.8683 |
11:27 ET | 300 | 1.87 |
11:29 ET | 1359 | 1.87 |
11:31 ET | 4642 | 1.8601 |
11:33 ET | 1900 | 1.87 |
11:36 ET | 7090 | 1.87 |
11:38 ET | 6623 | 1.87 |
11:40 ET | 8967 | 1.86 |
11:42 ET | 3716 | 1.855 |
11:44 ET | 300 | 1.86 |
11:45 ET | 950 | 1.86 |
11:47 ET | 300 | 1.86 |
11:49 ET | 300 | 1.86 |
11:51 ET | 500 | 1.86 |
11:54 ET | 482 | 1.86 |
11:56 ET | 4361 | 1.8607 |
11:58 ET | 19243 | 1.8499 |
12:00 ET | 24313 | 1.8499 |
12:02 ET | 399 | 1.86 |
12:03 ET | 1268 | 1.84 |
12:05 ET | 700 | 1.84 |
12:07 ET | 5777 | 1.86 |
12:09 ET | 350 | 1.8492 |
12:12 ET | 704 | 1.86 |
12:14 ET | 3238 | 1.84 |
12:16 ET | 959 | 1.845 |
12:18 ET | 34052 | 1.82 |
12:20 ET | 3366 | 1.82 |
12:21 ET | 60841 | 1.85 |
12:23 ET | 968 | 1.85 |
12:25 ET | 13541 | 1.8494 |
12:27 ET | 8300 | 1.8499 |
12:30 ET | 719 | 1.85 |
12:32 ET | 5400 | 1.85 |
12:34 ET | 600 | 1.86 |
12:36 ET | 19225 | 1.8485 |
12:38 ET | 17528 | 1.8516 |
12:41 ET | 1100 | 1.87 |
12:43 ET | 6569 | 1.86 |
12:45 ET | 559 | 1.86 |
12:48 ET | 3069 | 1.86 |
12:50 ET | 971 | 1.86 |
12:52 ET | 2411 | 1.86 |
12:54 ET | 1462 | 1.87 |
12:56 ET | 500 | 1.8601 |
12:57 ET | 432 | 1.87 |
12:59 ET | 13735 | 1.84 |
01:01 ET | 1300 | 1.85 |
01:03 ET | 1000 | 1.85 |
01:06 ET | 100 | 1.85 |
01:08 ET | 963 | 1.845 |
01:10 ET | 12320 | 1.845 |
01:12 ET | 1900 | 1.85 |
01:14 ET | 300 | 1.85 |
01:15 ET | 941 | 1.85 |
01:17 ET | 400 | 1.85 |
01:19 ET | 900 | 1.85 |
01:21 ET | 1106 | 1.85 |
01:24 ET | 6157 | 1.84 |
01:28 ET | 1400 | 1.85 |
01:30 ET | 11736 | 1.84 |
01:32 ET | 5535 | 1.8401 |
01:33 ET | 3700 | 1.85 |
01:35 ET | 23880 | 1.84 |
01:37 ET | 2722 | 1.84 |
01:39 ET | 200 | 1.84 |
01:42 ET | 200 | 1.84 |
01:44 ET | 14551 | 1.84 |
01:46 ET | 400 | 1.84 |
01:48 ET | 200 | 1.84 |
01:50 ET | 100 | 1.84 |
01:51 ET | 117190 | 1.8 |
01:55 ET | 621 | 1.81 |
01:57 ET | 10249 | 1.815 |
02:00 ET | 1125 | 1.82 |
02:02 ET | 9500 | 1.8102 |
02:04 ET | 479 | 1.8094 |
02:06 ET | 2901 | 1.805 |
02:08 ET | 36641 | 1.78 |
02:09 ET | 15616 | 1.78 |
02:11 ET | 8740 | 1.7906 |
02:13 ET | 8662 | 1.79 |
02:15 ET | 27193 | 1.7781 |
02:20 ET | 9725 | 1.775 |
02:22 ET | 14080 | 1.7799 |
02:24 ET | 100 | 1.78 |
02:26 ET | 4630 | 1.77 |
02:27 ET | 11261 | 1.76 |
02:29 ET | 2510 | 1.7686 |
02:31 ET | 4155 | 1.78 |
02:33 ET | 2300 | 1.79 |
02:36 ET | 5300 | 1.79 |
02:38 ET | 900 | 1.79 |
02:40 ET | 6767 | 1.79 |
02:42 ET | 1171 | 1.775 |
02:44 ET | 1000 | 1.77 |
02:45 ET | 36862 | 1.7799 |
02:47 ET | 3375 | 1.775 |
02:49 ET | 9509 | 1.77 |
02:51 ET | 25284 | 1.775 |
02:54 ET | 5918 | 1.7716 |
02:56 ET | 600 | 1.7797 |
02:58 ET | 14824 | 1.78 |
03:00 ET | 35940 | 1.76 |
03:02 ET | 10112 | 1.77 |
03:03 ET | 13537 | 1.78 |
03:05 ET | 6606 | 1.7609 |
03:07 ET | 4789 | 1.77 |
03:09 ET | 3377 | 1.77 |
03:12 ET | 2559 | 1.77 |
03:14 ET | 765 | 1.765 |
03:16 ET | 8448 | 1.77 |
03:18 ET | 2910 | 1.765 |
03:20 ET | 1225 | 1.7667 |
03:21 ET | 1000 | 1.77 |
03:23 ET | 20991 | 1.78 |
03:25 ET | 5700 | 1.79 |
03:27 ET | 15849 | 1.78 |
03:30 ET | 3424 | 1.78 |
03:32 ET | 6971 | 1.7795 |
03:34 ET | 1164 | 1.78 |
03:36 ET | 1458 | 1.78 |
03:38 ET | 800 | 1.78 |
03:39 ET | 5680 | 1.78 |
03:41 ET | 1700 | 1.78 |
03:43 ET | 2161 | 1.78 |
03:45 ET | 2400 | 1.78 |
03:48 ET | 4539 | 1.78 |
03:50 ET | 35288 | 1.8 |
03:52 ET | 45936 | 1.8 |
03:54 ET | 2910 | 1.8 |
03:56 ET | 4518 | 1.8 |
03:57 ET | 33847 | 1.8 |
03:59 ET | 18174 | 1.8 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Atossa Therapeutics Inc | 225.5M | -7.6x | --- |
Design Therapeutics Inc | 227.7M | -3.4x | --- |
X4 Pharmaceuticals Inc | 233.4M | -2.3x | --- |
Omeros Corp | 216.9M | -1.2x | --- |
Merrimack Pharmaceuticals Inc | 214.6M | -178.8x | --- |
Ovid Therapeutics Inc | 215.7M | -4.1x | --- |
Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing medicines in areas of unmet medical need in oncology with a focus on breast cancer. The Company’s lead drug candidate under development is oral (Z)-endoxifen, which the Company is developing in two settings: one to treat breast cancer by reducing tumor cell activity prior to surgery and another to reduce breast tissue density in women. Its programs under development include (Z)-endoxifen Programs, AT-H201, and other programs. (Z)-endoxifen is an active metabolite of tamoxifen, to treat and prevent breast cancer in high-risk women. It is developing a form of (Z)-endoxifen, which is administered orally for the potential treatment of breast cancer and reduction of breast density. AT-H201 is for lung injury caused by cancer treatments. AT-H201 consists of a combination of two drugs to treat other diseases. Its other programs include Immunotherapy/CAR-T Programs, which is in early stage of development.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $225.5M |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 125.3M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.20 |
EPS | $-0.24 |
Book Value | $0.93 |
P/E Ratio | -7.6x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.